Message from Leadership

We are truly grateful to all of our stakeholders for their continuing support.

In April 2026, I was appointed as President of Sysmex. Continuing to build on the foundation that Sysmex has created thus far, our company aims to achieve sustained growth through the realization of its long-term vision of “Together for a better healthcare journey”.

Changes in the healthcare environment have been happening at an unprecedented pace. This includes structural changes such as containment of medical expenditure in developed countries and improved access to healthcare in emerging and developing countries as well as advances in digital technologies and AI. At the same time, uncertainty has been increasing due to geopolitical risks and competition in securing talent. By seeing such environmental changes as opportunities for growth and honing our strengths, we firmly believe that they can be translated into steady growth.
 

As a company with direct connections to clinical settings worldwide, Sysmex has developed its business with the focus on in vitro diagnostics. Expanding our business beyond Japan, in the 30 years since the start of direct sales and customer care services in the U.K. in 1991, Sysmex has created a global network covering several countries and regions worldwide. As well as being a key strength it is an invaluable asset. In addition to fulfilling our responsibility for ensuring stability in product supplies, Sysmex has made sincere efforts to engage with our customers in order to obtain feedback from the sites of health testing. This has been reflected throughout the value chain in the form of product improvements and development of new products and services. By obtaining an in depth understanding of the medical care issues and onsite conditions of vitro diagnostics in each country and region in this way, Sysmex is able to address problems that customers themselves are not yet aware of and propose changes to normal concepts of in vitro diagnostics. The maximal use of this strength and continual provision of new value through innovation and high quality customer care have created a foundation for enduring relationships of trust with our customers.

In recognition of this, the Mid-Term Plan beginning in fiscal 2026 calls for thorough enhancement of the competitiveness and profitability of Sysmex’s diagnostics business. The 3-year period of the plan has therefore been positioned as crucial for returning to growth. The Mid-Term Plan calls for market launches of new products that exceed customer expectations as well as speeding up healthcare DX initiatives utilizing test data and digital technologies. In addition, Sysmex will reform corporate structures to make them more robust. This will involve establishing a cost structure that is not affected by global conditions or competitive environments and further enhancing stability in product supply systems in order to prevent any disruption in health testing. Doing this will ensure the unwavering trust of all of our stakeholders.

Furthermore, in order to position Sysmex as a leading company driving advances in global healthcare, we will not only increase the competitiveness of our business but also rigorously follow management practices focused on enhancing capital efficiency and governance. By achieving sustained increases in corporate value through constructive dialog with capital markets, Sysmex will help pave the way to a new future in healthcare.

We would be most grateful for the continuing support of all of our stakeholders in these endeavors. 

 Apr. 2026

Iwane Matsui
President